Hemanext

Lexington, United States Founded: 2004 • Age: 22 yrs
Technologies for blood and product storage are developed.

About Hemanext

Hemanext is a Healthcare company based in Lexington (United States) founded in 2004 by Martin Cannon. Technologies for blood and product storage are developed. Hemanext has raised $127.57 million across 10 funding rounds from investors including HHS. The company has 53 employees. Its chief executive, as recorded, is Andrew Dunham. Hemanext offers products and services including Hemanext ONE. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Preservation. Its legal entity is Hemanext, Inc. Its competitors include Brooks Automation, Bridge to Life and Cold Chain Technologies; 1 of its 3 listed competitors has raised funding.

Company details

Founded in 2004 and based in Lexington, United States, operations are focused on biotechnology for blood preservation. Two key technologies have been developed: Hemanext, which enables red blood cell storage under anaerobic conditions, and the MicroVascular Analyzer, used to measure red blood cell deformability. Applications include addressing hypercoagulability, inflammation, impaired perfusion, and immuno-modulation in therapeutic settings.

  • Headquarters Lexington, United States
  • Employees 53
  • Founders Martin Cannon
  • Sectors
    Healthcare
  • Phone
    โ€ขโ€ขโ€ขโ€ข โ€ขโ€ขโ€ขโ€ข
  • Website hemanext.com
  • Social LinkedIn X Facebook Instagram
  • Legal Name Hemanext, Inc.
Key Metrics
  • Total Equity Funding
    $127.57M (USD)

    in 10 rounds

  • Latest Funding Round
    $18.9M (USD), Series B

    Jul 2025

  • Investors
  • Employee Count
    53

Products & Services of Hemanext

Hemanext offers a comprehensive portfolio of products and services, including Hemanext ONE.

Hemanext ONE
Blood Processing System

Processes red blood cells to mitigate storage lesions and improve quality.

Funding Insights of Hemanext

Hemanext has successfully raised a total of $127.57M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $18.9 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $127.57M
  • Total Rounds 10
  • Last Round Series B โ€” $18.9M
  • First Round $1.89M

    (Mar 2009)

  • Investors Count 1

All 10 funding rounds of Hemanext with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2025$18.9MSeries Bโ€“โ€“
โ€“
Jan 2025$20MSeries Bโ€“โ€“
โ€“
Nov 2024$21.71MSeries Bโ€“โ€“
โ€“
Dec 2023$5.01MSeries Bโ€“โ€“
โ€“
Jun 2023$11.29MSeries Bโ€“โ€“
โ€“
Nov 2022$18MSeries Bโ€“โ€“
โ€“
Oct 2020$21.22MSeries Bโ€“โ€“
โ€“
Oct 2018$8.75MSeries Aโ€“โ€“
โ€“
Dec 2017$2.7MSeedโ€“โ€“
โ€“
Mar 2009$1.89MGrantโ€“โ€“
Valuation history

1 investors in total: 1 institutional.

Investors in Hemanext

Hemanext has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for Hemanext

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Hemanext

25 people are tracked at Hemanext (14 in leadership, 8 in board & advisors, 3 in team); the tracked headcount is 53.

NameRoleGroup
Martin Cannon
FounderLeadership
Andrew Dunham
CEO & CTOLeadership
Jill Buckley
VP, Human ResourcesLeadership
Daan Kok
EVP & General Manager, EMEALeadership
Laura Daniels
VP, Product DevelopmentLeadership
Mike McNamara
Chief Markets Officer, Investor, And Advisor To The Board Of DirectorsLeadership
Phyllis Haines Bergeron
Director, Field Implementation Program ManagerLeadership
Robert Haime
VP, Commercial OperationsLeadership
Eric Newman
CFOLeadership
Alex Marichal
Vice President Global Commercial DevelopmentLeadership
James N. Hourani
Associate Director Of Medical InformationLeadership
Laurel Omert
Chief Medical OfficerLeadership
Michael McGraw
Associate Director, Product DevelopmentLeadership
Suzanna van Straaten
Sr. Director Commercial And Market Access EMEALeadership
Steve Eckert
Board MemberBoard & advisors
David Testa
Board MemberBoard & advisors
Richard Perle
Board MemberBoard & advisors
William O'Neill
Board MemberBoard & advisors
Eduardo Avayú
Board MemberBoard & advisors
Guy Cogan
Board MemberBoard & advisors

5 more people are available in the full profile.

Premium access

Complete people profiles for Hemanext

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Hemanext

3 dated milestones of Hemanext across 21 years, from founding to its latest funding, stage changes and deals.

  1. Founded Hemanext is founded.
  2. Funding First funding round of $1.9M.
  3. Funding Latest funding round, Series B, of $18.9M.

Competitors of Hemanext

Hemanext has 3 listed competitors in our database, 1 of them funded. They include Brooks Automation, Bridge to Life and Cold Chain Technologies.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
brooks.com1978Chelmsford, United States1,928
Vacuum robots for semiconductor wafer handling are developed.
bridgetolife.com2012Columbia, United States$57M
Cold storage solutions for organ transplant preservation are provided.
coldchaintech.com2001Franklin, United States
Thermal packaging solutions and cold chain monitoring services are provided.
Premium access

Detailed competitors of Hemanext

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Hemanext

The website of Hemanext (hemanext.com) receives about 3.7K visits a month.

  • Monthly visits
    3.7K

    ▼ 55.4% vs previous month

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Hemanext (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track โ€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • โœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • โœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • โœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hemanext

Premium access

Complete news archive for Hemanext

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hemanext

Hemanext was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Hemanext is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Andrew Dunham is the CEO of Hemanext, as recorded in our data.

Hemanext is a funded company, having raised a total of $127.57M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.89M, raised on Mar 2009.

Hemanext has 53 employees.

Founded in 2004 and based in Lexington, United States, operations are focused on biotechnology for blood preservation. Two key technologies have been developed: Hemanext, which enables red blood cell storage under anaerobic conditions, and the MicroVascular Analyzer, used to measure red blood cell deformability. Applications include addressing hypercoagulability, inflammation, impaired perfusion, and immuno-modulation in therapeutic settings.

Hemanext's top competitors include Brooks Automation, Bridge to Life and Cold Chain Technologies.

Hemanext offers Hemanext ONE.

Hemanext has 1 investor. Key investors include HHS.

Hemanext operates through Hemanext, Inc..

Explore millions of companies โ€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals โ€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available